C5a receptor antagonism coming of age for vascular pathology

The Food and Drug Administration recently approved the new drug avacopan for a relatively rare disease, anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Avacopan is an antagonist of receptor-1 for anaphylatoxin C5a (C5aR1) that is the first one to meet all expectations of an orally bioavailable drug. Phar-macological effects of C5a on vascular tissue are reviewed; they are essentially indirect, via resident or infil-trating leukocytes, and largely mediated by vasoconstrictor prostanoids that are potentially thrombogenic. The in vivo acute neutropenic effect of C5a and various responses of isolated neutrophils to the peptide have been exploited in the preclinical development of avacopan, but not the prominent hemodynamic responses. Possible clinical risks and extension of therapeutic C5aR1 blockade are discussed. Therapeutic intervention on the blood-derived peptide C5a and on its G protein coupled receptor for specific forms of vascular injury contrasts with other current research approaches in vascular pathology, such as investigating the roles of cytokines and intracellular signaling.

Automated summary

The newly approved drug avacopan by the FDA is an orally bioavailable treatment for the rare disease ANCA-associated vasculitis, targeting inflammation-induced small vessel vasculitis by inhibiting the effects of C5a on vascular tissues through C5aR1 blockade.